Orlando, FL -- (SBWIRE) -- 10/02/2013 -- Hot Stock Profits provides investors and traders with valuable trading tools and content as well as micro-cap stock alerts via eMail and text messages. To Join Our Text Message Alerts Service Just Text The Word Stocks To 555888 From Your Cell Phone. Our Focus Today Is On Westinghouse Solar Inc (PINK:WEST), Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN).
Westinghouse Solar Inc (PINK:WEST) shares fell 13.05% to $0.0373. On September 20, 2013, the Company filed a Correction to the amendment to the Certificate of Incorporation to effectuate an increase in its number of authorized shares of Common Stock from 100 million to 500 million as the request to increase the number of authorized shares was inadvertently omitted from the September 19, 2013 amendment to the Certificate of Incorporation.
Additionally, the company on Sept. 10 announced that as part of implementing its planned transition to a leading provider of innovative residential and commercial solar power systems, it began receiving product from its new supplier and has fulfilled and shipped back orders to customers. The Company also reported that it is on schedule to receive additional product from its supplier with a revenue value of $800,000 that it expects to ship to customers by the end of the fourth quarter of this year.
Are investors worried about the recent updates with WEST? Find out with a free trend analysis HERE
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) shares declined 12.25% to $2.65. The law firm of Wolf Haldenstein Adler Freeman & Herz LLP on Sept. 30 announces that it is investigating potential federal securities claims against Achillion Pharmaceuticals Inc. ("Achilion" or "Company") (NASDAQ GS:ACHN) and certain of its officers and directors in connection with allegations that the Company made materially false and misleading statements regarding Company's experimental hepatitis C drug.
Additionally, the company on Sept. 27 provided an update on development of compounds in its pipeline of therapies for the treatment of chronic hepatitis C virus, or HCV. Achillion today received a response from the U. S. Food and Drug Administration, or FDA, on the clinical hold related to sovaprevir, Achillion's NS3 protease inhibitor.
Is ACHN going to continue its rally or drop like a rock? Find out with a free trend analysis HERE
Join Our Mobile SMS Alerts By Texting Stocks To 555888
HotStockProfits.com continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.
HotStockProfits.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit HotStockProfits.com website, for complete risks and disclosures.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)